Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Beta-Blockers in High-Risk Outpatients with Chronic Obstructive Pulmonary Disease are Associated with All-Cause Mortality - The STATUETTE Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Update on Asthma-COPD Overlap (ACO): A Narrative Review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Withdrawal of Inhaled Corticosteroids in Patients with COPD - A Prospective Observational Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Employment Status, Readmission and Mortality After Acute Exacerbation of COPD

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Inhaled Corticosteroid Therapy in Bronchiectasis is Associated with All-Cause Mortality: A Prospective Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Long-term predictors of severe exacerbations and mortality in a cohort of well-characterised adults with asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Characteristics of COPD Patients Prescribed ICS Managed in General Practice vs. Secondary Care

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: Beta-blockers have been proposed to improve COPD-related outcomes, yet studies report conflicting results. We aimed to investigate the effect of beta blockers on time-to-first exacerbation and all-cause mortality in high-risk COPD outpatients.

Methods: All COPD outpatients managed at the Department of Respiratory Medicine, Copenhagen University Hospital - Hvidovre, Denmark in 2016 were followed for 3.5 years in this retrospective, registry-based cohort study. Outcomes were time-to-first acute exacerbation of COPD (AECOPD) or death. The association was estimated using time-varying crude and multivariable Cox proportional hazard regression adjusted for age, sex, BMI, use of COPD medication, smoking status, cardiovascular disease and COPD severity.

Results: The cohort comprised 950 COPD outpatients, mean age 71 (SD 11) years, and FEV1 44% predicted (IQR 33%; 57%). The annual exacerbation rate was 0.88 (SD 1.68) and 211 patients (22%) had a history of hospitalization requiring AECOPD within 12 months. Of the enrolled patients, 247 (26%) were prescribed beta blockers. Beta-blocker use was associated, although with borderline significance, with increased all-cause mortality (HR 1.37 (95% CI, 0.99 to 1.89, p = 0.059)). On the other hand, beta blocker use did not reduce the risk of AECOPD (HR = 0.89 (95% CI 0.71 to 1.10; p = 0.270)), which remained non-significant after stratifying for severity of exacerbations.

Conclusion: We found an association between beta blocker use and all-cause mortality in high-risk COPD outpatients. No association was found between beta blocker use and risk of AECOPD.

Original languageEnglish
JournalInternational Journal of Chronic Obstructive Pulmonary Disease
Volume16
Pages (from-to)2397-2406
Number of pages10
ISSN1178-2005
DOIs
Publication statusPublished - 24 Aug 2021

    Research areas

  • Beta-blockers, Cardiovascular disease, Chronic obstructive pulmonary disease, Exacerbations, Mortality

ID: 67446579